- Clinical Pharmacology
- Next »
MDP Multidose Kit of Technetium Injection
CLINICAL PHARMACOLOGY
MDP Multidose Kit of Technetium Injection
During the initial 24 hours following intravenous injection of technetium Tc99m medronate about 50% of each dose is retained in the skeleton, and about 50% of each dose is excreted into the bladder.
Within 3 hours bone uptake is about 40-50% of each dose. Clearance of the complex from the blood is rapid and within the first 3-6 hours up to about 50% of each dose is cleared by urinary excretion.
Skeletal uptake of the complex occurs as a function of blood flow to bone and bone efficiency in extracting the complex. Bone mineral crystals are generally considered to be hydroxyapatite, and the complex appears to have an affinity for the hydroxyapatite crystals in bone.
- Clinical Pharmacology
- Next »
« Previous: MDP Multidose Kit of Technetium Injection - Overdosage & Contraindications
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Women's Health
Find out what women really need.
Vein Viewer
Ever have a blood test when the nurse can't find your vein? With this new infrared camera, one needle stick is all you have to See more WebMD Videos »
MDP Multidose Kit of Technetium Injection
New & Updated
Slideshows
2008 Election & Health Care on WebMD. Get Informed.
Updated & New
RxList does not provide medical advice, diagnosis or treatment.